Internal Medicine · Edmore, MI
NPI
1669411310
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1021 E. Main Street
Edmore, MI, 48829
Phone (989) 427-5320
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
5,420 services
Medicare patients, 2024
314
Average age 73
Drug cost, 2024
$1.5M
18,203 prescriptions
Company payments, 2025
$968
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Prakash Sarvepalli was code J1010 (injection, methylprednisolone acetate, 1 mg), 2,522 times for 33 patients. In total Prakash Sarvepalli billed 5,420 services in 75 codes, and Medicare paid $133K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-09-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,522 | 33 | $0.10 | $262 |
| 99214 Office E&M - Established | Office | 510 | 169 | $83.57 | $43K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 320 | 143 | $11.91 | $3,811 |
| 99454 E&M - Miscellaneous | Office | 224 | 35 | $32.17 | $7,206 |
| 99457 E&M - Miscellaneous | Office | 209 | 30 | $34.38 | $7,186 |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 156 | 24 | $0.33 | $51.56 |
| 96372 Injection Administration | Office | 140 | 43 | $9.90 | $1,386 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 120 | 120 | $120.82 | $14K |
| 99497 Care Management/Coordination | Office | 119 | 115 | $68.85 | $8,193 |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 118 | 118 | $17.07 | $2,014 |
| G0446 Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 108 | 108 | $23.83 | $2,573 |
| 83036 Blood Count | Office | 106 | 50 | $9.43 | $1,000 |
| 99309 SNF E&M | Office | 99 | 59 | $65.07 | $6,441 |
| 99406 Behavioral Health Services | Office | 78 | 24 | $13.87 | $1,082 |
| 99215 Office E&M - Established | Office | 75 | 47 | $130.06 | $9,755 |
By year: 2022 $204K for 4,639 services; 2023 $204K for 3,519 services; 2024 $133K for 5,420 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 106 | 50 | $9.43 | $1,000 |
Medicare prescription drug claims, 2024
In 2024, the drug Prakash Sarvepalli prescribed most often to Medicare patients was Atorvastatin Calcium, with 861 prescriptions and refills. In total Prakash Sarvepalli wrote 18,203 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 861 | 1,559 | 250 | $13K |
| Levothyroxine Sodium Generic | 699 | 1,126 | 160 | $8,691 |
| Furosemide Generic | 475 | 695 | 128 | $3,504 |
| Amlodipine Besylate Generic | 469 | 822 | 121 | $4,905 |
| Omeprazole Generic | 421 | 873 | 132 | $7,900 |
| Gabapentin Generic | 385 | 661 | 109 | $5,897 |
| Eliquis Apixaban | 382 | 490 | 79 | $203K |
| Metoprolol Succinate Generic | 380 | 746 | 111 | $5,906 |
| Metoprolol Tartrate Generic | 364 | 597 | 92 | $3,581 |
| Tamsulosin Hcl Generic | 323 | 661 | 104 | $6,518 |
| Lisinopril Generic | 319 | 597 | 99 | $2,556 |
| Ipratropium-Albuterol Ipratropium/Albuterol Sulfate | 294 | 294 | 26 | $6,507 |
| Potassium Chloride Generic | 293 | 457 | 83 | $11K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 242 | 296 | 55 | $15K |
| Clopidogrel Clopidogrel Bisulfate | 232 | 426 | 69 | $3,816 |
Brand drugs: 2,720 claims; generic drugs: 15,374 claims; opioid claims: 343.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Prakash Sarvepalli $968 ($968 in general payments such as food, travel and fees) from 21 companies. The largest payer was Abbvie Inc. with $177.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 11 | $177 |
| Eisai Inc. 4523.T | 4 | $97.6 |
| Novo Nordisk Inc NVO | 4 | $77.89 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $72.06 |
| Viatris Specialty LLC | 3 | $65.1 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 3 | $55.94 |
| Exact Sciences Corporation EXAS | 3 | $54.48 |
| Amgen Inc. AMGN | 3 | $50.71 |
| Xeris Pharmaceuticals, Inc. | 2 | $46.59 |
| Vanda Pharmaceuticals Inc. VNDA | 2 | $43.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.